Dermatol. praxi. 2021;15(4):203-206 [Onkologie. 2021:15(1):25-29]

Cutaneous complications in patients with malignant tumours

MUDr. Bc. Miroslav Důra
Dermatovenerologická klinika 1. LF UK a VFN v Praze

Skin changes play an important role in the course of anticancer therapy and in the dispensarisation of the patients with malignant tumours. The article briefly discusses the cutaneous complications in these patients. The text summarizes the risk of development of another primary cutaneous malignant tumour, the development of cutaneous or subcutaneous metastases and carcinomatous lymphadenopathy, cutaneous paraneoplastic syndromes, the adverse effects of the anticancer therapy and finally the cutaneous complications related to the disease progression. Particular attention is devoted to the specific types of cutaneous metastases, to the obligatory paraneoplastic syndromes, to cutaneous toxicity of immunotherapy and to complications of radiotherapy. The correct education of the patient is an important aspect of the success of the anticancer therapy. Because of it the patient could early recognize the signs of adverse effects of the anticancer therapy or the signs of disease progression.

Keywords: skin, toxicity, chemotherapy, radiotherapy, paraneoplastic syndrome, metastases, decubitus.

Published: November 23, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Důra M. Cutaneous complications in patients with malignant tumours. Dermatol. praxi. 2021;15(4):203-206.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jeyakumar A, Chua TC, Lam AK, et al. The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations. Crit Rev Oncol Hematol. 2020; 152: 102989. Go to original source... Go to PubMed...
    2. Vezzoni R, Conforti C, Vichi S, et al. Is There More Than One Road to Nevus-Associated Melanoma? Dermatol Pract Concept. 2020; 10(2): e2020028. Go to original source... Go to PubMed...
    3. Robert C. Traitement du mélanome par inhibiteurs de BRAF: manifestations cutanées. Montrouge, France: John Libbey Eurotext 2012: 45 s.
    4. Procházková M, Tomková H, Dolinská D, et al. Noduly umbiliku. Stručný přehled. Čes-slov Derm. 2020; 95(4): 148-151.
    5. Ravaioli GM, Starace M, Alessandrini AM, et al. Trichoscopy of Scalp Metastases. Int J Trichology 2019; 11(2): 86-87. Go to original source... Go to PubMed...
    6. Gresham E, Don Parsa F. Iatrogenic Implantation of Cancer Cells During Surgery. Hawaii J Health Soc Welf. 2020; 79(1): 4-6.
    7. Štork J, et al. Dermatovenerologie. Praha: Galén, 2013: 502 s.
    8. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv119-iv142. Go to original source... Go to PubMed...
    9. Lee M, Seetharamu N. An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab. Case Rep Dermatol Med. 2019; 2019: 4065437. Go to original source... Go to PubMed...
    10. Žemličková M. Poradiační poškození kůže, prevence a léčba. Podpůrná léčba 2019; 2: 5-8.
    11. Pokorná A, Saibertová S. Dekubity u onkologických pacientů - hodnocení stavu dekubitů a jejich prevence. Podpůrná léčba 2020; 3: 5-10.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.